ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHRE
Key facts
| Status | Awarded |
|---|---|
| Estimated value | $47,521,248 |
| Submission deadline | Deadline not published |
| Published | Jul 6, 2023 |
| Buyer | Office of Assistant Secretary for Preparedness and Response |
| Country | United States · DC |
| CPV code | NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN44 |
| Source | USAspending.gov Federal Contract Awards ↗ |
- Status
- Awarded
- Estimated value
- $47,521,248
- Submission deadline
- Deadline not published
- Published
- Jul 6, 2023
- Country
- United States
- CPV code
- NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN44
- Source
- USAspending.gov Federal Contract Awards
Contract outcome & evergreen alternatives
This notice is no longer open for submissions. The original remains available for reference.
| Awarded supplier / winner | Registration / LEI number | Country | Awarded contract amount | Award date |
|---|---|---|---|---|
| MELINTA THERAPEUTICS, LLC | US-UEI: H8K6F2A4KD49 | United States | $47,521,248 | Jul 6, 2023 |
Checked:
The original notice takes precedence. Its status and conditions can change after collection.
Description
ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN
Awarding Agency: Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response.
NAICS 541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
PSC AN44: HEALTH R&D SERVICES; HEALTH CARE - OTHER; R&D ADMINISTRATIVE EXPENSES.
Period of Performance: 2023-07-06 to 2030-06-30.